Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U1 small nuclear ribonucleoprotein (U1 snRNP) is a multi-subunit ribonucleoprotein complex involved in the recognition of the 5’ splice site at the exon-intron junction of precursor mRNA (pre-mRNA). It consists of U1 small nuclear RNA (164 bases), seven common Sm proteins (SmB/B', SmD1, SmD2, SmD3, SmE, SmF, SmG), and three U1-specific proteins (U1-70K, U1-A, U1-C). U1 snRNP binds to the 5’ splice site through base pairing between U1 snRNA and the pre-mRNA, thereby initiating spliceosome assembly. Its structure features a Sm protein ring core, with RNA stem-loops interacting with specific proteins. U1 snRNP is critical not only for canonical splicing but also plays roles in alternative polyadenylation regulation. Beyond its molecular functions, U1 snRNP has clinical relevance as an autoantigen in certain systemic autoimmune diseases, detected by specific autoantibodies[1][2][3][4][5][6][7][8].
When targeted experimentally, actions include blocking U1 snRNA—leading to inhibition of spliceosome assembly or altered splicing site usage (e.g., antisense oligonucleotides cause alternative polyadenylation and shorter transcripts)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U1 small nuclear ribonucleoprotein (U1 snRNP).